Levetiracetam Reverses Synaptic Deficits Produced by Overexpression of SV2A

Levetiracetam is an FDA-approved drug used to treat epilepsy and other disorders of the nervous system. Although it is known that levetiracetam binds the synaptic vesicle protein SV2A, how drug binding affects synaptic functioning remains unknown. Here we report that levetiracetam reverses the effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Nowack, Amy, Malarkey, Erik B., Yao, Jia, Bleckert, Adam, Hill, Jessica, Bajjalieh, Sandra M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248421/
https://www.ncbi.nlm.nih.gov/pubmed/22220214
http://dx.doi.org/10.1371/journal.pone.0029560

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248421/
https://www.ncbi.nlm.nih.gov/pubmed/22220214
http://dx.doi.org/10.1371/journal.pone.0029560

Ejemplares similares